Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials (Q43189964)
Jump to navigation
Jump to search
scientific article published in February 2010
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials |
scientific article published in February 2010 |
Statements
1 reference
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials (English)
1 reference
Bonaventura Clotet
1 reference
Joseph J Eron
1 reference
Jurgen K Rockstroh
1 reference
Mona R Loutfy
1 reference
Roy T Steigbigel
1 reference
David A Cooper
1 reference
Hedy Teppler
1 reference
Jose M Gatell
1 reference
Princy N Kumar
1 reference
Mauro Schechter
1 reference
Martin Markowitz
1 reference
Patrick Yeni
1 reference
Jeffrey L Lennox
1 reference
Jing Zhao
1 reference
Hong Wan
1 reference
Rand R Rhodes
1 reference
Kim M Strohmaier
1 reference
Richard J Barnard
1 reference
Robin D Isaacs
1 reference
Bach-Yen T Nguyen
1 reference
BENCHMRK Study Teamsa
1 reference
1 February 2010
1 reference
1 reference
Identifiers
1 reference